What is Amyotrophic Lateral Sclerosis (ALS)?
Amyotrophic Lateral Sclerosis (ALS)refers to a group of progressive neurological disorders that destroy the motor neurons responsible for controlling voluntary muscle movement. In Commonwealth medical systems, including Malaysia, ALS serves as the standard umbrella term, whereas Motor neurone disease(ALS)—or Lou Gehrig’s disease in North America—represents the most prevalent specific form. The condition selectively impairs physical movement while leaving cognitive and sensory functions intact.
Motor neurons originate in the brain’s motor cortex (Upper Motor Neurons) and extend through the brainstem and spinal cord (Lower Motor Neurons) to reach skeletal muscles throughout the body. In ALS, these vital nerve cells gradually degenerate and die. When communication signals fail, muscles undergo progressive wasting (atrophy) and weakness because they can no longer receive instructions to contract.
Crucially, ALS affects voluntary motor function almost exclusively. A patient’s sensory perception—vision, hearing, touch, taste, and smell—remains completely unaffected. Intellectual capacity, memory, emotional awareness, and autonomic bowel and bladder sphincter control also typically remain preserved. For the vast majority of patients, the mind remains sharp and observant even as physical mobility diminishes.
In Malaysia, public awareness of the condition deepened when national football legend Mokhtar Dahari (“Super Mokh”) was diagnosed in the late 1980s before passing away in 1991 at the age of 37. Globally, renowned theoretical physicist Stephen Hawking lived with a slow-progressing variant of ALS for more than five decades. According to data from the University Malaya Medical Centre (UMMC) Neurology Unit and ALS Malaysia, an estimated 2,000 to 3,000 individuals live with ALS nationwide, with approximately 600 new cases diagnosed each year across all major ethnic communities.
Early Symptoms and Warning Signs of ALS
Early symptoms of Motor Neurone Disease typically develop subtly as asymmetrical muscle weakness, persistent twitches, and unshakeable physical fatigue in a single limb or region. Because onset is gradual and painless, early warning signs are frequently mistaken for ordinary physical strain or common spinal issues. Recognizing these early presentations accelerates specialist referral to confirm diagnosis before severe functional loss occurs.
- Asymmetrical Onset: Initial weakness almost always begins on one side of the body or in a specific muscle group—such as grip weakness in one hand or dragging a single foot—before gradually spreading bilaterally.
- Fasciculations and Painful Cramps: Patients frequently notice fine, involuntary flickering or ripple-like muscle twitches under the skin, often accompanied by intense nighttime calf or foot cramps.
- Progressive Pathological Fatigue: Daily tasks like buttoning a shirt, climbing stairs, or carrying groceries trigger deep muscular exhaustion that does not resolve after sleep or physical rest.
- Early Respiratory Warning Signs: Weakening diaphragm and intercostal muscles can cause morning headaches, disturbed sleep, daytime grogginess, and orthopnea (shortness of breath when lying flat).
Limb-Onset ALS: Hand Clumsiness and Gait Imbalance
Limb-onset ALS accounts for approximately 70% to 75% of all cases, originating either in the upper or lower extremities before advancing through the central nervous system.
- Upper Limb Manifestations: Patients often experience declining fine motor coordination. Early signs include struggling to turn door keys, handle cutlery, tie shoelaces, or write legibly. Physical examination reveals progressive flattening and hollowing of the thenar muscles at the base of the thumb and the first dorsal interosseous space on the back of the hand.
- Lower Limb Manifestations: Ankle dorsiflexion weakness leads to “foot drop”, causing the toes to drag or scuff against the ground while walking. Individuals stumble easily on uneven surfaces, trip over flat rugs, and struggle to lift their knees when ascending stairs.
- Diagnostic Confusion: Limb-onset presentations are commonly misdiagnosed during initial general practitioner visits as cervical spondylosis, carpal tunnel syndrome, or lumbar disc herniation, delaying formal neurological referral.
Bulbar-Onset ALS: Slurred Speech and Swallowing Difficulties
Bulbar-onset ALS affects approximately 25% of patients, initially attacking the lower cranial motor nuclei in the brainstem that innervate the tongue, palate, throat, and vocal cords.
- Progressive Dysarthria: Weakened tongue and palate muscles cause speech to become slow, nasal, thick, and slurred. Words may sound muffled, as though the individual is speaking with a full mouth. Family members often suspect a mild transient ischaemic attack (mini-stroke).
- Progressive Dysphagia: Coordination deficits in pharyngeal swallowing make drinking thin liquids—such as water, tea, or clear broth—a frequent choking hazard. Meals take significantly longer to finish, and food pocketing occurs inside the cheeks.
- Sialorrhea (Saliva Pooling): Inability to swallow normal daily saliva production leads to persistent drooling or pooling in the mouth, requiring frequent dabbing with tissues.
- Accelerated Clinical Course: Bulbar-onset ALS generally progresses faster than limb-onset forms, making early assessment of nutritional safety and breathing capacity an urgent priority.
Causes, Genetics, and Risk Factors: Busting Hereditary Myths
The vast majority of Motor Neurone Disease cases occur sporadically without any prior family history, meaning the condition is generally not inherited by future generations. Clinical evidence confirms that over 90% to 95% of diagnoses arise from complex, multifactorial biological triggers rather than direct genetic inheritance. Genetic screening is only recommended in the rare 5% to 10% of cases where multiple immediate blood relatives have been diagnosed with ALS.
- Sporadic ALS (90% to 95% of Cases): In sporadic ALS, patients have no affected relatives. Medical research points to a convergence of cellular vulnerabilities, including glutamate excitotoxicity (excess excitatory neurotransmitters damaging neurons), mitochondrial dysfunction, neuroinflammation, oxidative stress, and impaired protein clearance. The children and siblings of someone with sporadic ALS face essentially the same baseline risk as the general population.
- Familial ALS (5% to 10% of Cases): Familial ALS follows an autosomal dominant inheritance pattern, meaning an affected parent carries a 50% chance of passing the genetic variant to their offspring. Identified causative genes include SOD1, C9orf72, FUS, and TARDBP. Clinical genetic testing and pre-test genetic counselling are advised exclusively when two or more first-degree relatives have a documented history of motor neurone disease.
- Malaysian Demographics and Risk Factors: ALS most commonly appears between the ages of 40 and 70, with a median age of diagnosis around 55 years. While it can occasionally affect younger adults in their late twenties or thirties, men have a slightly higher incidence than women (ratio of roughly 1.2 to 1.5:1). Chronic cigarette smoking represents the most consistently validated environmental risk factor for accelerating neurodegenerative onset.
How is Motor Neurone Disease Diagnosed? Key Clinical Pathways
Diagnosing Motor Neurone Disease requires a rigorous exclusion-based pathway because no single laboratory test or brain scan can independently confirm the condition. Malaysian neurologists conduct comprehensive clinical, neurophysiological, and imaging assessments to rule out mimicking neurological disorders while identifying concurrent Upper and Lower Motor Neuron dysfunction. The diagnostic process relies on standardized clinical frameworks such as the revised El Escorial and Gold Coast criteria.
- Comprehensive Neurological Examination: A consultant neurologist evaluates deep tendon reflexes, muscle tone, and power. The hallmark of classic ALS is the coexistence of Upper Motor Neuron (UMN) signs (such as brisk hyperreflexia, muscle spasticity, and a positive Babinski reflex) alongside Lower Motor Neuron (LMN) signs (such as muscle wasting, weakness, and active fasciculations) in the same anatomical body region.
- Electromyography (EMG) and Nerve Conduction Studies (NCS): EMG serves as the gold-standard diagnostic tool. A fine needle electrode inserted into affected and seemingly unaffected muscles detects widespread active denervation (fibrillation potentials, positive sharp waves) and chronic reinnervation across bulbar, cervical, thoracic, and lumbosacral regions. Conduction studies verify that sensory nerves remain healthy, helping exclude demyelinating polyneuropathies.
- High-Resolution MRI of Brain and Spine: Magnetic resonance imaging of the brain, cervical spine, and lumbar spine is essential to rule out compressive structural lesions, including cervical spondylotic myelopathy, spinal cord compression, brainstem stroke, multiple sclerosis (MS), or central nervous system tumours.
- Comprehensive Blood and Cerebrospinal Fluid (CSF) Panels: Blood tests rule out reversible mimickers such as heavy metal toxicity (lead, mercury), severe vitamin B12 deficiency, thyroid dysfunction, and autoimmune neuromuscular disorders like Myasthenia Gravis (AChR/MuSK antibodies) or Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). A lumbar puncture may be performed to evaluate CSF protein and exclude neuroinfections.
- Standardised International Diagnostic Criteria: Malaysian specialists apply the revised El Escorial criteria and the newer Gold Coast diagnostic criteria (introduced in 2020). The Gold Coast consensus simplifies diagnosis to “ALS” or “Not ALS” based on documented progressive motor impairment, combined UMN and LMN signs in at least one body region (or LMN signs alone across two regions), and the strict exclusion of other neurological diseases.
Current Treatment Options and Disease Management
While no curative therapy exists for Motor Neurone Disease, comprehensive multidisciplinary care combined with disease-modifying medications significantly slows functional decline and extends life expectancy. Integrated clinical teams bring together neurologists, palliative specialists, physiotherapists, and speech therapists to manage complications proactively. Alongside approved pharmaceuticals, early management focuses on maintaining physical comfort and avoiding hazardous unproven interventions.
- Multidisciplinary Team (MDT) Care: Clinical trials demonstrate that regular management through a specialized multidisciplinary ALS clinic extends patient survival by 7 to 12 months—an impact equal to or greater than available medications—while dramatically improving patient safety, functional independence, and emotional well-being.
- Disease-Modifying Pharmaceuticals:
- Riluzole: An oral neuroprotective tablet that inhibits glutamate release at nerve synapses, reducing neurotoxicity. Clinical studies show that continuous Riluzole use extends overall tracheostomy-free survival by two to three months.
- Edaravone: A potent antioxidant and free-radical scavenger delivered via intravenous infusion cycles. Approved in Malaysia and several international jurisdictions, it helps slow the rate of functional decline on the ALSFRS-R (ALS Functional Rating Scale–Revised) in eligible early-stage patients.
- Targeted Gene Therapies: In patients with confirmed SOD1 mutations, targeted antisense oligonucleotide therapy—such as Tofersen (Qalsody)—has been approved internationally to lower toxic SOD1 protein accumulation, offering hope for precision genetic medicine.
- Symptomatic Pharmacological Support: Neurologists prescribe Baclofen or Tizanidine to alleviate painful muscle cramps and spasticity; anticholinergic agents (such as Glycopyrrolate, Amitriptyline, or Scopolamine transdermal patches) to control excess saliva and drooling; and suitable analgesics for joint stiffness.
- Critical Warning on Commercial Stem Cell Injections: Patients and caregivers are strongly cautioned against spending family savings on commercial, unregulated stem cell treatments offered by overseas or private aesthetic clinics. There is no verified clinical trial evidence demonstrating that stem cell therapy restores lost motor neurons or halts ALS progression. Unregulated intrathecal or intravenous injections carry severe risks of chemical meningitis, sepsis, systemic infection, and life-threatening immune reactions.
Living with ALS: Progression Stages, Nutrition, Breathing & Assistive Care
Living with Motor Neurone Disease requires adapting care strategies across distinct stages to protect respiratory function, maintain safe nutrition, and preserve communication independence. Proactive interventions, such as timely feeding tube placement and non-invasive breathing support, prevent life-threatening complications like aspiration pneumonia. A coordinated home care routine helps patients maintain dignity and quality of life as physical abilities evolve.
| Disease Stage |
Functional Changes |
Core Care Goals |
Assistive Devices & Interventions |
| Early Stage |
Mild weakness in one limb, fine hand clumsiness, gait instability, occasional muscle twitches, or slight speech changes. |
Fall prevention, joint range of motion, energy conservation, baseline speech and swallow assessment. |
Walking sticks, ankle-foot orthosis (AFO), ergonomic cutlery, button hooks, and food thickeners. |
| Middle Stage |
Weakness spreading to both sides, limited walking ability, frequent choking on liquids, slurred speech, morning fatigue. |
Safe nutrition, aspiration prevention, airway clearance, assisted mobility, and alternative communication. |
Wheelchair, voice-banking software, communication alphabet boards, and elective PEG feeding tube placement. |
| Late Stage |
Severe four-limb paralysis, loss of verbal speech, profound swallow deficit, marked respiratory muscle weakness. |
Aspiration prevention, non-invasive ventilation, pressure injury prevention, and palliative comfort care. |
BiPAP ventilator, cough assist machine, alternating pressure air mattress, and eye-tracking speech computers. |
Nutritional Interventions and Safe Swallowing
Malnutrition and dehydration accelerate muscle loss in ALS, while dysphagia carries a serious risk of aspiration pneumonia—one of the leading causes of acute hospitalisation.
- Diet Texture Modification: Transition from thin liquids to thickened fluids using commercial starch- or gum-based food thickeners. Pureed dishes, puddings, and soft steamed foods reduce choking risks. Patients must eat in an upright, 90-degree sitting posture with their chin tucked slightly downward toward the chest while swallowing.
- Timely Percutaneous Endoscopic Gastrostomy (PEG): When eating takes over an hour per meal, coughing becomes frequent, or weight drops by more than 10%, a PEG feeding tube should be placed. During this minor endoscopic procedure, a soft feeding tube is inserted directly into the stomach through the abdominal wall. PEG secures hydration, liquid nutrition, and oral medications safely. Elective PEG placement is strongly recommended before respiratory vital capacity (FVC) drops below 50%, when sedation carries higher risks. Patients with a PEG tube can still taste small amounts of pleasant foods orally if medically safe.
Respiratory Management and Ventilation
Respiratory failure caused by diaphragm and intercostal muscle weakness is the most critical complication in ALS. Regular pulmonary function monitoring with spirometry (especially Forced Vital Capacity, or FVC) allows for timely respiratory support.
- Non-Invasive Ventilation (NIV / BiPAP): When daytime somnolence, morning headaches, or unrefreshing sleep occur—or when FVC falls below 50%—nocturnal BiPAP should be initiated. A comfortable facial or nasal mask delivers pressurized room air, resting tired breathing muscles, improving oxygenation, and clearing trapped carbon dioxide. BiPAP dramatically enhances sleep quality and adds months of comfortable survival.
- Mechanical Airway Clearance: Weakened expiratory muscles reduce the ability to clear mucus. Mechanical cough assist devices (insufflator-exsufflator) push air into the lungs and quickly pull it back, producing an artificial, productive cough that prevents mucus plugs and chest infections.
Mobility, Postural Support, and Pressure Relief
As muscle atrophy limits active movement, careful positioning preserves joint comfort and skin integrity.
- Preventing Joint Contractures: Caregivers should perform gentle, full-range-of-motion passive stretches for shoulders, hips, knees, and ankles twice daily. This relieves muscle tightness and prevents frozen joints.
- Pressure Injury Prevention: Immobile individuals must be repositioned at least every two hours. An alternating pressure ripple mattress, silicone heel protectors, and specialized gel cushions for wheelchairs distribute pressure and prevent painful decubitus bedsores.
Augmentative and Alternative Communication (AAC)
Loss of speech does not mean loss of intellect or personal connection. A gradual approach to assistive communication ensures patients retain their personal voice throughout every phase of illness.
- Low-Tech Tools: In early-to-mid stages, low-tech communication boards featuring alphabet grids, common words, or pictograms allow patients to indicate choices using finger-pointing or laser pointers attached to glasses.
- Eye-Tracking Speech Systems: When hand and arm mobility declines, advanced eye-tracking computers (such as Tobii Dynavox) transform eye movements and blinks into text-to-speech outputs. Patients can draft messages, send emails, browse the internet, and maintain rich conversations with loved ones entirely through ocular control.
Malaysian Healthcare Ecosystem, Financial Aid & Patient Support
Malaysian patients diagnosed with Motor Neurone Disease can tap into an integrated network of specialized public clinics, non-profit equipment loan programmes, and statutory financial assistance schemes. Navigating these healthcare and social security safety nets early alleviates significant financial and logistical strain for caregiving families. From subsidized medical equipment to disability pensions and EPF withdrawals, essential resources are accessible nationwide.
- Specialized Hospital Multidisciplinary Clinics:
- University Malaya Medical Centre (UMMC): Established Malaysia’s first dedicated ALS Multidisciplinary Clinic. Patients consult consultant neurologists, palliative care physicians, neuro-rehabilitation experts, speech therapists, and clinical dietitians during a single coordinated clinic session, minimizing exhausting travel.
- Hospital Kuala Lumpur (HKL) & Hospital Canselor Tuanku Muhriz (HCTM): Offer comprehensive neuromuscular specialist clinics capable of advanced neurophysiology, non-invasive ventilation titration, and coordinated nutritional tube placement.
- MND Malaysia (Persatuan Penyakit Motor Neuron Malaysia):
- Founded in 2014, MND Malaysia is the sole national non-profit organization dedicated entirely to MND patients and caregivers.
- Medical Equipment Loan Bank: High-end medical devices like BiPAP machines, cough assist units, hospital beds, wheelchairs, and eye-tracking computers can cost between RM5,000 and RM20,000 to purchase outright. MND Malaysia maintains a heavily subsidized or free equipment loan pool for registered member families.
- Caregiver Training and Support: Offers hands-on nursing workshops, home visits, and informal “Teh Tarik” peer support circles connecting newly diagnosed families with experienced caregivers. Contact them via WhatsApp (+6012-901 3798) or their official portal.
- Community Palliative and Hospice Services:
- Organizations such as Hospis Malaysia (serving the Klang Valley), Kasih Hospice Care Society, and Penang Hospice Society provide free community palliative care.
- With a doctor’s referral letter, palliative nurse teams visit the patient’s home to assist with pain management, respiratory comfort, secretion control, loan basic assistive equipment, and provide bereavement support for family members.
- JKM OKU Card (Kad Orang Kurang Upaya):
- Patients diagnosed with ALS qualify for an OKU card under the physical disability category (Kurang Upaya Fizikal) via the Department of Social Welfare (Jabatan Kebajikan Masyarakat / JKM).
- An application form endorsed by a registered government specialist doctor unlocks substantial benefits, including complete medical fee exemptions for consultations, diagnostics, and wards at Ministry of Health (KKM) public hospitals.
- EPF / KWSP Account 2 Health Withdrawal:
- The Employees Provident Fund (KWSP) recognizes Motor Neurone Disease under its approved list of critical illnesses.
- Members under age 55 can apply for a Health Withdrawal from Account 2 (Akaun Sejahtera) to cover direct medical treatments, hospitalization costs, and approved assistive healthcare equipment (such as BiPAP machines and wheelchairs) for themselves, their spouse, children, parents, or siblings. Applications are submitted online via the KWSP i-Akaun portal with medical reports from treating specialists.
- SOCSO / PERKESO Invalidity Scheme (Skim Keilatan):
- Working Malaysians under 60 who contribute to SOCSO are covered 24 hours a day under the Invalidity Scheme (Skim Keilatan) against non-work-related permanent disability.
- If progressive ALS impairs an employee’s earning capacity by at least one-third (1/3) of a normal healthy worker’s ability, they can file for Pencen Ilat (Invalidity Pension) using SOCSO Form 34, supported by hospital medical reports.
- Successful applicants receive a monthly pension for life. If the medical board (Jemaah Doktor) confirms that the patient is bedridden or requires constant full-time caregiver attendance, an additional Constant Attendance Allowance (Elaun Layanan Sentiasa) is awarded monthly.
- Private Critical Illness (CI) Insurance:
- Motor Neurone Disease is explicitly covered under the Life Insurance Association of Malaysia (LIAM) standard 36/39 critical illness definitions. Policies pay out a lump-sum living benefit upon submission of specialist clinical reports and neurophysiological proof verifying unequivocal diagnosis and permanent neurological deficits.
Frequently Asked Questions
Can Motor Neurone Disease be inherited by my children?
In more than 90% to 95% of cases, Motor Neurone Disease is sporadic and cannot be directly inherited by your children. Sporadic ALS arises from a complex combination of cellular, aging, and environmental factors, meaning offspring have no greater statistical risk than the general public. Only 5% to 10% of cases are familial ALS, which follows an autosomal dominant inheritance pattern linked to genes such as SOD1 and C9orf72. Genetic testing is only warranted when two or more immediate blood relatives have been clinically diagnosed with MND.
Do muscle twitches (fasciculations) and cramps mean I have ALS?
Isolated muscle twitches rarely indicate Motor Neurone Disease. Benign Fasciculation Syndrome (BFS) is extremely common in healthy adults, frequently brought on by fatigue, mental stress, sleep deprivation, excess caffeine consumption, or mild electrolyte imbalances. In ALS, muscle twitches are persistent, widespread, and always accompanied by progressive muscle weakness, loss of dexterity, and visible muscle atrophy. If your twitches occur without muscle wasting or weakness, they are almost certainly harmless.
Can I claim SOCSO (PERKESO) or private critical illness insurance for ALS in Malaysia?
Yes, Malaysian patients have access to both statutory and private financial coverage. Insured employees under age 60 can apply for an Invalidity Pension (Pencen Ilat) through SOCSO’s Skim Keilatan if ALS permanently prevents them from earning a living. Bedridden patients requiring full-time caregiver assistance can also qualify for the Constant Attendance Allowance (Elaun Layanan Sentiasa). Additionally, standard private critical illness policies in Malaysia cover Motor Neurone Disease, paying out lump-sum benefits once specialist medical reports confirm permanent neurological deficits.
Can EPF / KWSP Account 2 savings be withdrawn to cover ALS medical bills and equipment?
Yes, EPF allows members to withdraw funds from Account 2 (Akaun Sejahtera) under the Health Withdrawal scheme. Motor Neurone Disease qualifies under approved neurological critical illnesses. Members can utilize their Account 2 savings to cover clinical treatment costs, hospitalization, and essential assistive medical equipment (such as BiPAP ventilators and wheelchairs) for themselves, their spouse, children, parents, or siblings. The application requires medical verification from the treating hospital specialist submitted via the KWSP i-Akaun portal.
What is the difference between ALS and other forms of Motor Neurone Disease like PLS or PMA?
Motor Neurone Disease is an umbrella term covering several clinical subtypes based on which motor nerves degenerate. Amyotrophic Lateral Sclerosis (ALS) is the most common form, damaging both Upper Motor Neurons (UMN) in the brain and Lower Motor Neurons (LMN) in the spinal cord. In contrast, Primary Lateral Sclerosis (PLS) affects purely Upper Motor Neurons, resulting in spasticity without muscle wasting and having a much slower progression. Progressive Muscular Atrophy (PMA) selectively affects Lower Motor Neurons, causing muscle atrophy and weakness without hyperreflexia.
Where can families rent or borrow BiPAP machines and eye-tracking computers locally in Malaysia?
Families can borrow high-cost medical equipment through ALS Malaysia (Persatuan Penyakit Motor Neuron Malaysia). The association operates a dedicated equipment loan library that provides BiPAP ventilators, cough assist machines, hospital beds, wheelchairs, and eye-tracking computers at little to no rental cost for registered member families. Community hospice societies like Hospis Malaysia and Kasih Hospice also loan basic home-care equipment free of charge to registered patients within their operational coverage areas.
Does ALS affect a patient’s memory, intellect, or emotional awareness?
In the vast majority of patients, cognitive intellect, long-term memory, and emotional comprehension remain fully intact throughout the disease. Because ALS targets voluntary motor neurons, patients stay fully conscious, sensory-aware, and alert to their environment. A small subset of patients (around 10% to 15%) may experience frontotemporal cognitive or behavioural changes. Caregivers and healthcare staff should always address ALS patients as fully cognizant, capable adults and involve them directly in every personal and medical decision.
Why should patients avoid commercial stem cell therapy or unproven alternative treatments for MND?
Commercial stem cell therapies for ALS have not demonstrated safety or therapeutic efficacy in verified clinical trials. Unregulated commercial clinics often market costly injections that carry severe medical dangers, including life-threatening chemical meningitis, systemic infections, and catastrophic immune reactions. Furthermore, pursuing unproven remedies depletes valuable financial resources that are far better invested in proven interventions—such as non-invasive ventilation (BiPAP), PEG nutritional tubes, physiotherapy, and certified multidisciplinary supportive care.
This article is for reference only; the actual coverage terms are subject to the policy.
This article is for reference only and is not medical advice. Please consult a registered doctor if you have any concerns.
Sources
- mndmalaysia.org
- semanticscholar.org
- alsnewstoday.com
- mndmalaysia.org
- nih.gov
- alsnewstoday.com
- galencentre.org
- rumc.edu.my
- homage.com.my
- fda.gov
- als.org
- als-mnd.org
- mndmalaysia.org
- mndmalaysia.org
- facebook.com
- hospismalaysia.org
- kasihfoundation.org
- skrine.com
- maybank2u.com.my
- perkeso.gov.my
- perkeso.gov.my
- perkeso.gov.my
